Underlining the reversal prognostic impact of NDRG2 in basal- compared to luminal-type breast cancer, the tumor suppressor gene SFRP1, a key antagonist of the WNT/β-catenin signaling pathway, also tends to be associated with unfavorable patients’ outcome (Kaplan Meier-Plotter data) in basal-like breast cancer. This evidence concerns the gene SFRP1 and breast carcinoma.